<DOC>
	<DOCNO>NCT01522664</DOCNO>
	<brief_summary>This multicenter , open-label study ass safety pharmacokinetics DEDN6526A patient metastatic unresectable melanoma . Cohorts patient receive escalate dos DEDN6526A intravenous infusion Day 1 21-day cycle . In absence disease progression unacceptable toxicity , patient may continue receive DEDN6552A 17 cycle ( 1 year ) .</brief_summary>
	<brief_title>A Study DEDN6526A Patients With Metastatic Unresectable Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Histologically confirm metastatic melanoma ( AJCC stage IV ) unresectable melanoma ( AJCC Stage III ) Prior failure &gt; /= 1 prior treatment regimens metastatic unresectable melanoma due disease progression unacceptable toxicity standard therapy available Measurable disease accord RECIST criterion Adequate bone marrow , liver renal function Female patient childbearing potential male patient female partner childbearing potential must agree use one highly effective form nonhormonal contraception two effective form nonhormonal contraception course study treatment 6 month last dose study treatment Treatment cytotoxic antibody base therapy within 21 day prior first dose study treatment , anticancer therapy within 5 halflives therapy prior first dose study treatment Known active infection ( include HIV atypical mycobacterial disease , exclude fungal infection nail bed ) Current Grad &gt; /= 2 toxicity ( except alopecia anorexia ) prior therapy Grade &gt; /= 2 peripheral neuropathy History severe allergic anaphylactic reaction monoclonal antibody therapy ( recombinant antibodyrelated fusion protein ) Clinically significant history liver disease , include viral hepatitis , current alcohol abuse , cirrhosis Untreated active central nervous system ( CNS ) metastases ( progress require anticonvulsant corticosteroid symptomatic control ) Evidence significant uncontrolled concomitant disease disorder Pregnant lactating woman Prior treatment antibodydrug conjugate ( ADC ) compound contain monomethyl auristatin E ( MMAE ) treatment melanoma Previous participation clinical trial within 30 day day first study drug administration ( Cycle 1 , Day 1 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>